These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1797567)

  • 1. CCK-8-related C-terminal tetrapeptides: affinities for central CCKB and peripheral CCKA receptors.
    Harhammer R; Schäfer U; Henklein P; Ott T; Repke H
    Eur J Pharmacol; 1991 Dec; 209(3):263-6. PubMed ID: 1797567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
    J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
    Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
    J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic cholecystokinin analogues with high selectivity for central receptors.
    Charpentier B; Pelaprat D; Durieux C; Dor A; Reibaud M; Blanchard JC; Roques BP
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1968-72. PubMed ID: 3162318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264.
    Durieux C; Ruiz-Gayo M; Roques BP
    Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
    Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
    Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
    Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
    Boyle SJ; Tang KW; Woodruff GN; McKnight AT
    Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological studies on CCKB receptors in guinea pig synaptoneurosomes.
    Galas MC; Bernad N; Martinez J
    Eur J Pharmacol; 1992 May; 226(1):35-41. PubMed ID: 1327841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice.
    Hernando F; Fuentes JA; Roques BP; Ruiz-Gayo M
    Eur J Pharmacol; 1994 Aug; 261(3):257-63. PubMed ID: 7813546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin increases intracellular Ca2+ concentration in the Human JURKAT T Lymphocyte cell line.
    Lignon MF; Bernad N; Martinez J
    Eur J Pharmacol; 1993 May; 245(3):241-6. PubMed ID: 8335062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve.
    Corp ES; McQuade J; Moran TH; Smith GP
    Brain Res; 1993 Sep; 623(1):161-6. PubMed ID: 8221086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological effects of newly synthesized cholecystokinin analogs.
    Verspohl EJ; LaMura M
    Horm Res; 2000; 53(4):177-84. PubMed ID: 11044801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
    Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
    Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists.
    Gonzalez-Muniz R; Bergeron F; Marseigne I; Durieux C; Roques BP
    J Med Chem; 1990 Dec; 33(12):3199-204. PubMed ID: 1701834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity.
    Jagerschmidt A; Guillaume-Rousselet N; Vikland ML; Goudreau N; Maigret B; Roques BP
    Eur J Pharmacol; 1996 Jan; 296(1):97-106. PubMed ID: 8720482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of YM022: its CCKB/gastrin receptor binding profile and antagonism to CCK-8-induced Ca2+ mobilization.
    Saita Y; Yazawa H; Honma Y; Nishida A; Miyata K; Honda K
    Eur J Pharmacol; 1994 Oct; 269(2):249-54. PubMed ID: 7851501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
    Gully D; Fréhel D; Marcy C; Spinazzé A; Lespy L; Neliat G; Maffrand JP; Le Fur G
    Eur J Pharmacol; 1993 Feb; 232(1):13-9. PubMed ID: 7681406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCKB receptor activation results in increased [3H]thymidine incorporation in rat glioma C6 cells.
    Kaufmann R; Henklein P; Nowak G
    Neuropeptides; 1995 Nov; 29(5):241-4. PubMed ID: 8587658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.